References
- Ogura S, Tachibanaki T, Wise AD. Aging issues in the United States and Japan. University of Chicago Press; Chicago, IL, USA: 2001
- Yamada T, Chen C, Yamada T, et al. Pharmaceutical price control policy, pharmaceutical innovation, and health durability. Open Pharmacoecon Health Econ J 2010;2:34-46
- Boucher BA. Formularies, pharmacists, and influences on the decision-making process. Pharmacotherapy 2010;30(6 pt 2):33-4
- World Generics Market 2008-2013. Visiongain Ltd; London, UK: 2008
- Pharmaceutical Key Trends 2011: Generics Market Overview. Report No: HC00062-008. Datamonitor Healthcare; London, UK: 2011
- US Department of Commerce International Trade administration. Public Hearing on The U.S. Department of Commerce’s Study on International Drug Pricing as Required by Section 1123 of the Medicare Prescription Drug, Improvement and Modernization Act of 2003. Available from: www.ita.doc.gov/td/health/gpha81204.pdf [Last accessed 5 May 2013]
- Solan F, Hsieh CR. Health economic. The MIT Press; Cambridge, MA, USA: 2012
- Elovainio R. Performance incentives for health in high-income countries key issues and lessons learned. World Health Report (2010) Background Paper, No 32, Health systems financing. World Health Organization; 2010. Available from: www.who.int/healthsystems/topics/financing/healthreport/32PBF.pdf [Last accessed 5 May 2013]
- Riku J. Current situation for generic drugs in Japan. J Generic Med 2005;2(3):219-31
- Iizuka T. Physician agency and adoption of generic pharmaceuticals. Am Econ Rev 2012;102(6):2826-58
- Shimura H, Masuda S, Kimura H. Analyzing the generic penetration trend in the Japanese dispensing market by therapeutic category. J Generic Med 2012;9(2):55-62
- Kanavos P, Gemmill M. Pharmaceutical pricing and reimbursement in Europe. Scrip reports. Scrip; London, UK: 2005
- Organization for economic co-operation and development. 2009. Available from: www.oecd.org/competition/abuse/46138891.pdf
- Mrazek MF, Mossialos E. Increasing demand while decreasing costs of generic medicines. Lancet 2000;356(9244):1784-5
- Kanavos P, Costa-Font J, Seeley E. Competition in off-patent drug markets: issues, regulation and evidence. Econ Policy 2008;23(55):499-544
- Garattini L, Tediosi F. A comparative analysis of generics markets in five European countries. Health Policy 2000;51(3):149-62
- Ogura S, Hagino T. Why do the Japanese spend so much on drugs? In: Ogura S, Tachibanaki T, Wise D, editors. NBER book labor markets and firm benefit policies in Japan and the United States. University of Chicago Press; Chicago, IL, USA: 2003. p. 229-66
- Organization for economic co-operation and development. Major brake in health spending growth as governments cut budgets in the crisis, says OECD. Available from: www.oecd.org/newsroom/major-brake-in-health-spending-growth-as-governments-cut-budgets-in-the-crisis.htm [Last accessed 4 May2013]
- Murata C, Yamada T, Chen CC, et al. Barriers to health care among the elderly in Japan. Int J Environ Res Public Health 2010;7(4):1330-41
- Iizuka T, Kubo K. The generic drug market in Japan: will it finally take off? Health Econ Policy Law 2010;6(3):369-89
- Shepard A. Generic medicines: essential contributors to the long term health of society. Available from: www.imshealth.com/imshealth/Global/Content/IMS%20Institute/Documents/Generics_Medicines.pdf [Last accessed 27 May 2013]
- Yoshida E, Toumi M. Generic drug market access in Japan. Abstract book ISPOR 15th Annual European Congress; 3 – 7 November 2012; Berlin, Germany
- Ministry of Health, Labour and Welfare of Japan. Program to Promote Use of Generic Drugs in Japan. Available from: www.japta.or.jp/pdf/CPhIJapan2012_siryou_E2.pdf [Last accessed 4 May 2013]
- US FDA. Generic Competition and Drug Prices. Available from: www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm129385.htm [Last accessed 4 May 2013]
- Masuda S. The market exclusivity period for new drugs in Japan: overview of intellectual property protection and related regulations. J Generic Med 2008;5(2):121-30
- US Department of Commerce, International Trade Administration. Pharmaceutical Price, Controls in OECD Countries, Implications for US Consumers, Pricing, Research and Development, and Innovation. Available from: www.ita.doc.gov/td/chemicals/drugpricingstudy.pdf [Last accessed 6 May 2013]
- Hotez PJ, Cohen R, Mimura C, et al. Strengthening mechanisms to prioritize, coordinate, finance, and execute R&D to meet health needs in developing countries. Discussion Paper. Institute of Medicine, Washington, DC, USA; 2013. Available from: iom.edu/∼/media/Files/Perspectives-Files/2013/Discussion-Papers/BGH-GlobalHealthRD.pdf [Last accessed 5 May 2013]
- Danzon PM, Chao L. Does regulation drive out competition in pharmaceutical markets? J Law Econ 2000;43(2):311-57
- Ministry of Health, Labour and Welfare of Japan. Drug Price Survey. Available from: www.mhlw.go.jp/bunya/iryouhoken/iryouhoken01/dl/01_eng.pdf [Last accessed 5 May 2013]
- Ministry of Health, Labour and Welfare of Japan. Available from: www.mhlw.go.jp/stf/shingi/2r9852000002qdbx-att/2r9852000002qdfd.pdf [Last accessed 6 May 2013]
- Fair Trade Commission Decision of August 24, 2006 (the 772nd Commissioners’ Meeting); Disposition (95) Kung Ch’u Tzu No. 095130. Available from: www.apeccp.org.tw/doc/Taipei/Case/dec2006/2006-779-772.html
- Ministry of Health, Labour and Welfare of Japan. Available from: www.mhlw.go.jp/stf/shingi/2r9852000002yofs-att/2r9852000002yojn.pdf [Last accessed 6 May 2013]
- Yakuji Nippou Mail News, 17 April 2006. Available from: www.yakuji.co.jp/entry273.html [Last accessed 6 May 2013]
- Ministry of Health, Labour and Welfare of Japan. Available from: www.mhlw.go.jp/bunya/iryou/kouhatu-iyaku/dl/16.pdf [Last accessed 6 May 2013]
- Pharmaceutical and Medical Device Regulatory Science Society of Japan PMRJ foundation site. Japanese Orange books. Available from: www.pmrj.jp/eng/index_e.html [Accessed 6 May 2013]
- Ministry of Health, Labour and Welfare of Japan. Available from: www.mhlw.go.jp/bunya/iryou/kouhatu-iyaku/dl/11.pdf [Last accessed 6 May 2013]
- Ministry of Health, Labour and Welfare of Japan. 2010. Available from: apps.who.int/medicinedocs/documents/s18577en/s18577en.pdf
- Ministry of Health, Labour and Welfare of Japan. Available from: www.mhlw.go.jp/topics/medias/year/12/gaiyou.html [Last accessed 6 May 2013]
- Qlife. Available from: www.qlife.co.jp/news/2978.html [Last accessed 6 May 2013]
- Japan Pharmaceutical Association. Available from: www.nichiyaku.or.jp/?cat=1729 [Last accessed 4 May 2013]
- Thomson Reuters. The Japanese generic drug market: opportunities and Strategies for Success. Available from: http://thomsonreuters.com/business-unit/science/pdf/ls/newport-japanese-generics.pdf [Last accessed 6 May 2013]
- English Regulatory Information Task Force, Japan Pharmaceutical Manufacturers Association. Pharmaceutical Administration and Regulations in Japan; 2012. Available from: www.jpma.or.jp/english/parj/pdf/2012.pdf [Last accessed 5 May 2013]
- Jakovljevic BM, Jankovic MS. Bioequivalence studies. Acta Medica Medianae 2006;45(4):50-5
- Nakai K, Fujita M, Ogata H. International harmonization of bioequivalence studies and issues shared in common. Yakugaku Zasshi 2000;120(11):1193-200
- Van der Meersch A, Dechartres A, Ravaud P. Quality of reporting of bioequivalence trials comparing generic to brand name drugs: a methodological systematic review. PLoS One 2011;6(8):e23611
- Oishi M, Chiba K, Fukushima T, et al. Different truncation methods of AUC between Japan and the EU for bioequivalence assessment: influence on the regulatory judgment. Drug Metab Pharmacokinet 2012;27(6):658-62
- Otsuka M, Tomita H, Otsuka K, et al. International harmonization of generic drugs: in vitro dissolution tests for Japanese and American generic tablets. Biomed Mater Eng 2006;16(2):129-35
- Yamashita S, Tachiki H. Analysis of risk factors in human bioequivalence study that incur bioinequivalence of oral drug products. Mol Pharm 2009;6(1):48-59
- Yamada M, Welty TE. Generic substitution of antiepileptic drugs: a systematic review of prospective and retrospective studies. Ann Pharmacother 2011;45(11):1406-15
- Al-Baradie RS. Generic substitution of anti-epileptic drugs. A needed battle? Neurosciences (Riyadh) 2008;13(3):211-16
- Bialer M. Generic products of antiepileptic drugs (AEDs): is it an issue? Epilepsia 2007;48(10):1825-32
- Colaizzi JL, Lowenthal DT. Critical therapeutic categories: a contraindication to generic substitution? Clin Ther 1986;8(4):370-9
- Fujimura S, Watanabe A. Generic antibiotics in Japan. J Infect Chemother 2012;18(4):421-7
- Simoens S. Developing the Japanese generic medicines market: what can we learn from Europe? J Generic Med 2009;6(2):129-35
- Iijima H, Kurosaki T, Kamei M, et al. Valuing the drug information provided for generics in setting the price of generic drugs in Japan. Drug Inf J 2004;38(3):265-72.2004
- Onda M, Kanematsu M, Kitamura T, et al. Availability of drug information on bioequivalence of generic products – findings of graduate interns at a university pharmacy. Yakugaku Zasshi 2007;127(7):1159-66
- Iijima H, Koshimizu T, Shiragami M. Objective evaluation of generic-specific drug information. Yakugaku Zasshi 2007;127(3):541-5
- Iijima H, Kamei M, Koshimizu T, Shiragami M. Evaluation of information for generic drugs based on importance and necessity. Yakugaku Zasshi 2005;125(9):739-47
- Arano I, Imaeda T. Current and future views from pharmaceutical industry perspectives on development of antidepressants. Nihon Shinkei Seishin Yakurigaku Zasshi 2011;31(4):181-6
- Organisation for Economic Co-operation and Development. Generic Pharmaceuticals; 2009. Available from: www.oecd.org/competition/abuse/46138891.pdf [Last accessed 5 May 2013]
- Manning R, Smith R. Brand-name versus generic drugs. Health Aff (Millwood) 2011;30(10):2027-8
- Correa CM. Ownership of knowledge – the role of patents in pharmaceutical R&D. Bull World Health Organ 2004;82(10):784-7; discussion 787-790
- Serajuddin HK, Serajuddin AT. Value of pharmaceuticals: ensuring the future of research and development. J Am Pharm Assoc (2003) 2006;46(4):511-16
- Aoki R, Kubo K, Yamane H. Indian Patent Policy and Public Health: implications from the Japanese Experience. Institute of Developing Economies, Japan External Trade Organization (JETRO). Published in IDE Discussion Paper No. 57. 2006. Available from: http://ir.ide.go.jp/dspace/bitstream/2344/140/3/ARRIDE_Discussion_No.057_kubo.pdf [Last accessed 5 May 2013]
- Ramlall VV. The Pharmaceutical Industry in The Great White North and Land of the Rising Sun: a Comparison of Regulatory Data Protection in Canada and Japan, IIP Bulletin 2004. Available from: www.iip.or.jp/e/e_summary/pdf/detail2003/e15_12.pdf [Last accessed 5 May 2013]
- Danzon PM, Furukawa MF. Prices and availability of biopharmaceuticals: an international comparison. Health Aff (Millwood) 2006;25(5):1353-62
- Umemura M. Reconsidering Japan’s underperformance in pharmaceuticals: evidence from Japan’s anticancer drug sector. Enterp Soc 2010;11(3):560-93
- Hudson J. Generic take-up in the pharmaceutical market following patent expiry: a multi-country study. Int Rev Law Econ 2000;20(2):205-21
- Ministry of Health, Labour and Welfare of Japan. MHLW Notification N 041001 of PFSB, 1st April 2007
- Allen M. Japan’s Generic Drug Market: A Giant Time Machine for Investors. Available from: http://seekingalpha.com/instablog/613337-michael-allen/176544-japan-s-generic-drug-market-a-giant-time-machine-for-investors [Last accessed 2 May 2013]
- Tessensohn J. Reversal of fortune – pharmaceutical experimental use and patent infringement in Japan. J Int Legal Stud 1998;1(4):50-1
- Tessensohn J, Yamamoto S. Crystal clear: a landmark pharma patent victory in Japan. J Intellect Prop Law Pract 2008;3(7):473-8
- Frank RG. The ongoing regulation of generic drugs. N Engl J Med 2007;357(20):1993-6
- Hassali MA, Shafie AA, Jamshed S, et al. Consumers’ views on generic medicines: a review of the literature. Int J Pharm Pract 2009;17(2):79-88
- Hoshi S, Kimura H. Questionnaire on the awareness of generic drugs among outpatients and medical staff. Drug Discov Ther 2008;2(3):194-9
- Iizuka T. Experts’ agency problems: evidence from the prescription drug market in Japan. Rand J Econ 2007;38(3):844-62
- Kobayashi E, Karigome H, Sakurada T, et al. Patients’ attitudes towards generic drug substitution in Japan. Health Policy 2011;99(1):60-5
- The World Medicines Situation; 2004. World Health Organization. Available from: http://apps.who.int/medicinedocs/en/d/Js6160e/ [Last accessed 3 January 2014]
- Pharmaceuticals Sector Fiche (16 December 2011). Available from: http://trade.ec.europa.eu/doclib/docs/2012/january/tradoc_148988.pdf
- The Pharmaceutical Industry and Global Health – Facts and Figures 2012. Available from: www.ifpma.org/fileadmin/content/Publication/2013/IFPMA_-_Facts_And_Figures_2012_LowResSinglePage.pdf [Last accessed 3 January 2014]
- Teva and Kowa Announce Strategic Partnership to Create a Leading Generic Pharmaceutical Company in Japan. Available from: www.sec.gov/Archives/edgar/containers/fix031/818686/000081868608000141/kowa240908.pdf [Last accessed 5 May 2013]
- Japan External Trade Organization. Available from: www.jetro.go.jp/en/topics/topics_20130225_01.html [Last accessed 6 May 2013]
- Das S. Bulk drug makers eye Japanese generic market. Available from: www.business-standard.com/article/companies/bulk-drug-makers-eye-japanese-generic-market-113033100311_1.html [Last Accessed 06 May 2013]
- Kobayashi H, Obara T, Takahashi N, et al. Evaluation of efficacy and safety of manidipine hydrochloride among essential hypertensive patients: substitution from branded product (Calslot) to Generic Product (Manidip). Yakugaku Zasshi 2007;127(12):2045-50
- Kesselheim AS, Misono AS, Lee JL, et al. Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis. JAMA 2008;300(21):2514-26
- Kesselheim AS, Stedman MR, Bubrick EJ, et al. Seizure outcomes following the use of generic versus brand-name antiepileptic drugs: a systematic review and meta-analysis. Drugs 2010;70(5):605-21
- Teruyo Arato, PhD, Review Director of PMDA, Recent Regulations of Biosimilars in Japan. Available from: www.pmda.go.jp/regulatory/file/english_presentation/biologics/B-E1arato.pdf [Last accessed 3 January 2014]
- Shaping the biosimilars opportunity: a global perspective on the evolving biosimilars landscape. Available from: www.imshealth.com/ims/Global/Content/Home%20Page%20Content/IMS%20News/Biosimilars_Whitepaper.pdf [Last accessed 3 January 2014]
- Peters JR, Hixon DR, Conner DP, et al. Generic drugs – safe, effective, and affordable. Dermatol Ther 2009;22(3):229-40